Cellebrite DI Ltd. (NASDAQ:CLBT) Sees Significant Growth in Short Interest

Cellebrite DI Ltd. (NASDAQ:CLBT) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 3,900,000 shares, a growth of 29.6% from the August 15th total of 3,010,000 shares. Currently, 5.9% of the company’s stock are sold short. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is presently 2.5 days.

Wall Street Analyst Weigh In

A number of research firms recently commented on CLBT. Bank of America lifted their price target on Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Lake Street Capital upped their price target on Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Craig Hallum boosted their target price on shares of Cellebrite DI from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Needham & Company LLC raised their price target on shares of Cellebrite DI from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $17.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quadrature Capital Ltd acquired a new position in Cellebrite DI during the 4th quarter worth $2,222,000. Capstone Investment Advisors LLC acquired a new stake in Cellebrite DI in the first quarter worth about $870,000. Sei Investments Co. grew its position in Cellebrite DI by 44.7% in the 1st quarter. Sei Investments Co. now owns 121,166 shares of the company’s stock valued at $1,343,000 after buying an additional 37,408 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in Cellebrite DI by 7.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 7,086,158 shares of the company’s stock valued at $56,446,000 after buying an additional 514,858 shares during the period. Finally, Inspire Investing LLC acquired a new position in Cellebrite DI during the 1st quarter valued at about $862,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Up 0.1 %

CLBT traded up $0.01 during trading on Monday, reaching $17.52. 1,002,900 shares of the company were exchanged, compared to its average volume of 1,136,852. Cellebrite DI has a 52 week low of $6.36 and a 52 week high of $17.61. The firm has a 50 day moving average of $14.70 and a 200 day moving average of $12.53. The stock has a market cap of $3.61 billion, a P/E ratio of -30.21, a PEG ratio of 2.33 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, August 15th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The business had revenue of $95.70 million during the quarter, compared to analyst estimates of $91.94 million. During the same quarter in the prior year, the firm earned $0.05 earnings per share. The company’s quarterly revenue was up 24.8% on a year-over-year basis. As a group, analysts forecast that Cellebrite DI will post 0.31 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.